Nanoparticle-Based Combination Therapy Enhances Fulvestrant Efficacy and Overcomes Tumor Resistance in ER-Positive Breast Cancer

富维斯特朗 乳腺癌 药理学 耐受性 医学 雌激素受体 癌症研究 癌症 联合疗法 不利影响 内科学
作者
Bozhao Li,Feilong Qi,Fei Zhu,Zefang Lu,Meiqi Wang,Tianjiao Chu,Suying Wu,Jingyan Wei,Zhenchuan Song,Saraswati V. Sukumar,Cheng Zhang,Jiang‐Fei Xu,Suping Li,Guangjun Nie
出处
期刊:Cancer Research [American Association for Cancer Research]
卷期号:83 (17): 2924-2937 被引量:19
标识
DOI:10.1158/0008-5472.can-22-3559
摘要

Nanoparticles (NP) spanning diverse materials and properties have the potential to encapsulate and to protect a wide range of therapeutic cargos to increase bioavailability, to prevent undesired degradation, and to mitigate toxicity. Fulvestrant, a selective estrogen receptor degrader, is commonly used for treating patients with estrogen receptor (ER)-positive breast cancer, but its broad and continual application is limited by poor solubility, invasive muscle administration, and drug resistance. Here, we developed an active targeting motif-modified, intravenously injectable, hydrophilic NP that encapsulates fulvestrant to facilitate its delivery via the bloodstream to tumors, improving bioavailability and systemic tolerability. In addition, the NP was coloaded with abemaciclib, an inhibitor of cyclin-dependent kinases 4 and 6 (CDK4/6), to prevent the development of drug resistance associated with long-term fulvestrant treatment. Targeting peptide modifications on the NP surface assisted in the site-specific release of the drugs to ensure specific toxicity in the tumor tissues and to spare normal tissue. The NP formulation (PPFA-cRGD) exhibited efficient tumor cell killing in both in vitro organoid models and in vivo orthotopic ER-positive breast cancer models without apparent adverse effects, as verified in mouse and Bama miniature pig models. This NP-based therapeutic provides an opportunity for continual and extensive clinical application of fulvestrant, thus indicating its promise as a treatment option for patients with ER-positive breast cancer. SIGNIFICANCE: A smart nanomedicine encapsulating fulvestrant to improve its half-life, bioavailability, and tumor-targeting and coloaded with CDK4/6 inhibitor abemaciclib to block resistance is a safe and effective therapy for ER-positive breast cancer.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
852的应助被SYX采纳,获得10
刚刚
weako发布了新的文献求助10
刚刚
薛雨佳发布了新的文献求助10
1秒前
canjian1943完成签到,获得积分10
1秒前
Lucas的应助被负责幻巧采纳,获得10
1秒前
汉堡包的应助被winwin采纳,获得10
2秒前
王大锤发布了新的文献求助10
2秒前
3秒前
3秒前
ttt完成签到,获得积分10
3秒前
半圭为璋发布了新的文献求助10
4秒前
4秒前
虚幻如容发布了新的文献求助10
4秒前
4秒前
卓卓完成签到,获得积分10
6秒前
6秒前
鸽子二号完成签到,获得积分10
6秒前
8秒前
月半完成签到 ,获得积分10
8秒前
隐形曼青的应助被啊琴黎采纳,获得10
8秒前
wangyiyi发布了新的文献求助30
9秒前
mengfeiyang发布了新的文献求助10
9秒前
9秒前
10秒前
10秒前
10秒前
10秒前
甘草次酸完成签到,获得积分10
10秒前
10秒前
含蓄的小鸽子完成签到,获得积分10
10秒前
科研通AI6.3的应助被海鹏采纳,获得10
11秒前
11秒前
11秒前
wanci的应助被Keoki采纳,获得10
11秒前
盐盐发布了新的文献求助10
12秒前
天天快乐的应助被ALITTLE采纳,获得10
12秒前
Happy发布了新的文献求助10
13秒前
13秒前
半圭为璋完成签到,获得积分10
14秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
Grapes 1000
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8178617
求助须知:如何正确求助?哪些是违规求助? 9569413
关于积分的说明 21804370
捐赠科研通 7773649
什么是DOI,文献DOI怎么找? 3432878
关于科研通互助平台的介绍 2556873
邀请新用户注册赠送积分活动 2478478